Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults

Crucell Holland BV240 enrolled

Overview

Study design: Single-blind (subject and observer-blinded), active-controlled, randomized \[6:2:1:2:1; CL184 + purified vero cell rabies vaccine (PVRV) vs. human rabies immune globulin (HRIG) + PVRV vs. placebo + PVRV vs. CL184 + human diploid cell vaccine (HDCV) vs. placebo + HDCV\], mono-center study Study objectives: Primary: To evaluate the safety of CL184 in combination with PVRV in healthy adult subjects. Secondary: To evaluate the safety of HRIG or placebo in combination with PVRV and to evaluate the safety of CL184 or placebo in combination with HDCV in healthy adult subjects. To evaluate the rabies virus neutralizing activity (RVNA) after administration of CL184 or placebo in combination with PVRV, of HRIG in combination with PVRV, and of CL184 or placebo in combination with HDCV in healthy adult subjects. To evaluate the pharmacokinetics of the monoclonal antibodies (mAbs).

This study was designed to explore and obtain further safety and RVNA data on CL184 in comparison to HRIG and placebo as part of a classical post-exposure prophylaxis (PEP) regimen. This regimen will be applied as simulated PEP regimen to healthy subjects (i.e. in a pre-exposure setting) in this study. A comparison with placebo combined with each rabies vaccine was included to differentiate between the contribution of immune globulin and vaccine and to investigate potential interactions between immune globulin and vaccine. RVNA provided by CL184 or HRIG, as well as vaccination response will be checked regularly during the study and booster doses can be applied after the study, if necessary. In addition pharmacokinetic data will be collected.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

240

Interventions

Rabies virus-specific monoclonal antibodiesBIOLOGICAL

CL184 20 IU/kg intramuscularly on Day 0.

human polyclonal rabies immune globulin (HRIG)BIOLOGICAL

HRIG 20 IU/kg intramuscularly on Day 0.

PlaceboBIOLOGICAL

Placebo intramuscularly on Day 0.

Human diploid cell vaccine (HDCV)BIOLOGICAL

Rabies vaccine (HDCV) given on Days 0, 3, 7, 14, and 28.

Purified verocell rabies vaccine (PVRV)BIOLOGICAL

Rabies vaccine (PVRV) given on Days 0, 3, 7, 14, and 28.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female subject aged ≥18 to ≤55 years * Subjects free of obvious health-problems or with stable conditions or medications * Body mass index between ≥18 to ≤30 kg/m2 * Abstinence from sexual intercourse or use of adequate contraception from the date of screening up to Day 90 * Male subjects must agree that they will not donate sperm from the first check-in until Day 90 * Subject signed written informed consent Exclusion Criteria: * Prior history of active or passive rabies immunization * Clinically significant acute illness or infection including fever (≥38 °C) within 2 weeks before first dosing * History and/or family history of clinically significant immunodeficiency or auto-immune disease * Planned immunization with live vaccines during the coming 3 months after first dosing * Chronic (longer than 14 days) administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of investigational medicinal product

Outcomes

Primary Outcomes

Number of participants with adverse events as a measure of safety

Assessed by recording unsolicited adverse events, solicited local and systemic adverse events, and pain at the injection site (assessed on a Visual Analog Scale from Day 0 to Day 3); routine safety laboratory assessed on Days -1, 1, 3, 7, 42, and 90; ECG and vital signs assessed on Days -1, 7, and 90.

Time frame: 90 days

Secondary Outcomes

Rabies virus neutralizing activity